Pneumagen


Illetrop provides hands-on senior executive support to biotechnology companies. Based in Scotland but operating internationally, Illetrop represents a number of companies from the UK, Asia and mainland Europe including Pneumagen a company focused on developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs). Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Pneumagen has spun-off, through a demerger, a separate company called Omideon Limited. Omideon is focused on progressing the research and development of mCBMs in oncology . Please visit the website for more information. www.omideon.com

Contact Pneumagen via their website


News archive

27/05/2020   Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19...more

08/05/2020   Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s ”The Nine”...more

28/04/2020   Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections...more

17/03/2020   Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections...more

12/11/2019   Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019...more

15/10/2019   Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code